Loading patent…
AssigneeZoetis W LLC
InventorsANDRÉ JESTIN, EMMANUEL ALBINA, PIERRE LE CANN, PHILIPPE BLANCHARD, EVELYNE HUTET, CLAIRE ARNAULD, CATHERINE TRUONG, DOMINIQUE MAHE, ROLAND CARIOLET, FRANÇOIS MADEC
Estimating the term…
The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
1-14. (canceled)
An immunogenic composition consisting essentially of porcine circovirus type B (PCVB) ORF2 protein and one or more veterinary-acceptable carriers for use in the reduction of the concomitant infection in pigs or a herd of pigs cause by PCVB and one or more viral, bacterial, or fungal pathogens other than PCVB.
An immunogenic composition consisting essentially of porcine circovirus type B (PCVB) ORF2 protein and one or more veterinary-acceptable carriers.
An immunogenic composition consisting essentially of porcine circovirus type B (PCVB) ORF2 protein and one or more veterinary-acceptable carriers, wherein said ORF2 protein comprises an amino acid sequence having at least 90% identity to SEQ ID NO:26.
A method of inducing an immune response against porcine circovirus type B (PCVB), said method comprising administering one dose of a composition comprising a polypeptide encoded by a nucleic acid having at least 90% identity to SEQ ID NO:25 and a pharmaceutically or veterinarily acceptable carrier.
A method of inducing an immune response against porcine circovirus type B (PCVB), said method comprising administering one dose of a composition comprising a polypeptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO:26 and a pharmaceutically or veterinarily acceptable carrier.
Dependencies are inferred from the claim text.